Post Surgical Infections
Destiny Pharma’s lead product exeporfinium chloride (XF-73) focuses on addressing the burden caused by one of the major Gram positive bacteria, Staphylococcus aureus, a leading world cause of post-surgical infection.
A third of the human population carry the bacteria S. aureus, typically in the nose. S. aureus carriers are at a significantly higher risk of acquiring a post-surgical infection.
While this risk has been understood for some time, recent clinical evaluations have been undertaken to establish the effectiveness and value of preventing all S. aureus (both methicillin resistant S. aureus (MRSA) and all other S. aureus strains) infections within hospitals.
The main approach in SA infection prevention has been to treat patients who carry the bacteria prior to surgery to reduce the risk of infection. This has been achieved predominately by the use of an intra-nasal antibiotics (e.g. mupirocin) and antiseptic (e.g. chlorhexidine) body washes. Early approaches in this area focused on MRSA – particularly among higher infection risk surgeries.
However, Bode et al. demonstrated that treatment of all S. aureus, (MRSA & all other strains of S. aureus) in higher risk surgeries led to a >60% reduction in post-surgical SA infections. The recognition of the benefit of treatment of all S. aureus represents about a six fold increase in the patient population benefiting, a figure of >20 million per year in the USA & Europe alone.
A number of key surgical guidelines in the US and EU/RoW now recommend preventative treatment of all S. aureus (MRSA & all other S. aureus strains) in patients undergoing at risk surgeries.
However, the use of existing preventative treatments are severely limited by the existence of /and fear of generating the emergence of resistance.
Staphylococcus aureus is a gram-positive bacteria and is frequently found in the nose, respiratory tract, and on the skin. S. aureus can cause a range of illnesses, from minor skin infections to life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome, bacteraemia, and sepsis. Each year, around 500,000 patients in hospitals of the United States contract a staphylococcal infection, chiefly by S. aureus.
Whilst methicillin resistant S. aureus (MRSA) is the better known form of S. aureus, methicillin sensitive S. aureus (MSSA) which includes S. aureus that are resistant to other antibiotics (often more than one) is responsible for 93% of all reported bacteraemias (blood infection) in England from the UK Government’s latest figures.